A biopharma partner would not be concerned with having an independent chairman of the board. Partners deal with operating management.
I could see it being an issue for a potential BP partner if it anticipated a plan/possibility of getting a director placed on AVXL's board. Interesting development considered a significant, material event by the BOD.